<DOC>
	<DOCNO>NCT00130065</DOCNO>
	<brief_summary>The purpose study determine whether folic acid , often routinely give pregnant woman prevent birth defect anemia , affect efficacy sulfadoxine-pyrimethamine , another drug routinely give pregnant woman highly malarious area , prevention adverse effect malaria pregnancy .</brief_summary>
	<brief_title>The Effect Folic Acid Efficacy Sulfadoxine-pyrimethamine Pregnant Women Western Kenya</brief_title>
	<detailed_description>In malaria endemic area sub-Saharan Africa , pregnant woman , especially primi- secundi-gravidae , likely placental peripheral parasitemia Plasmodium falciparum non-pregnant woman . Adverse consequence malaria pregnancy include maternal anemia , low birth weight new bear . Low birth weight know important risk factor infant mortality . Intermittent preventive treatment ( IPT ) sulfadoxine-pyrimethamine ( SP ) pregnancy mitigate adverse effect malaria pregnancy current standard care area high malaria transmission sub-Saharan Africa , recommend World Health Organization . SP act inhibit parasite enzyme metabolism folic acid . However , vitro study indicate folic acid antagonize antimalarial parasite activity SP . Furthermore , one West African study , supplementary folic acid compromise antimalarial efficacy SP child acute malaria age 6 month 12 year . Folic acid requirement increase pregnancy , supplementation folic acid pregnancy recommend . Although country daily supplementation 400 600 microgram consider sufficient , logistical reason daily recommend dose Kenya 5 mg folic acid pregnancy . It unknown whether folic acid supplementation might compromise efficacy IPT SP pregnant woman live malaria endemic area . Several study show HIV-seropositive pregnant woman high risk malaria HIV-seronegative pregnant woman . In addition , HIV-infected woman likely anemic compare HIV-uninfected woman . A study also show HIV-seropositive woman appear respond well IPT SP compare HIV-seronegative pregnant woman . In recent study pregnant woman Zimbabwe , HIV-infection negative predictor serum folate , author suggest may reduce intake absorption , increase catabolism HIV-infected pregnant woman . Because HIV-seropositive woman group may different folic acid status ( potential different reaction folic acid supplementation ) HIV-seronegative woman , important ass HIV-status study participant . It also important confirm difference exist HIV-seropositive HIV-seronegative woman efficacy SP clearance peripheral parasitemia . Comparison : Parasitemic pregnant woman randomize receive either SP folic acid 5 mg , SP folic acid 0.4 mg , SP placebo . The placebo folic acid 0.4 mg give two week , replace folic acid 5 mg .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Parasitemia parasite density ≥ 500 parasites/microliter Gestational age &gt; 16 week &lt; 35 week Willingness provide blood sample participate HIV counsel test Available follow entire study period Hemoglobin &gt; 7 g/dl Age 1545 year Use folate last 4 week Gestational age &lt; 16 week &gt; 35 week History allergy sulfonamide unknown drug Intake sulfacontaining drug 4aminoquinolones previous month A urine test positive sulfacompounds Sickle cell disease Concomitant diseases need treatment cotrimoxazole sulfacontaining drug Hemoglobin &lt; 7 g/dl Severe malaria serious medical condition require hospitalization and/or additional treatment . Clinical danger sign severe malaria include prostration , impaired consciousness , respiratory distress , multiple convulsion , circulatory collapse , pulmonary oedema , abnormal bleeding , jaundice , hemoglobinuria . Laboratory sign severe malaria include severe anemia ( hemoglobin &lt; 7 g/dl ) , hypoglycemia , acidosis , hyperlactataemia , hyperparasitaemia ( parasitemia &gt; 100,000 parasites/µl ) , renal impairment</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Sulfadoxine-pyrimethamine</keyword>
	<keyword>Folic acid</keyword>
	<keyword>Folate</keyword>
</DOC>